We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amicus Says No NDA for Fabry Disease Treatment This Year
Amicus Says No NDA for Fabry Disease Treatment This Year
The FDA has asked Amicus Therapeutics to integrate data from two Phase 3 studies of its Fabry disease treatment migalastat, pushing back its NDA filing until early 2016.